Kathleen Van Dyk1,2, Catherine M Crespi1,2,3, Julienne E Bower1,2,4, Steven A Castellon1,5, Laura Petersen2, Patricia A Ganz2,6,7. 1. Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles, Los Angeles, California. 2. Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California. 3. Department of Biostatistics, Fielding School of Public Health, University of California at Los Angeles, Los Angeles, California. 4. Department of Psychology, University of California at Los Angeles, Los Angeles, California. 5. VA Greater Los Angeles Healthcare System, Los Angeles, California. 6. David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. 7. Department of Health Policy and Management, Fielding School of Public Health, University of California at Los Angeles, Los Angeles, California.
Abstract
BACKGROUND: After treatment of primary breast cancer, endocrine therapy (ET) is prescribed for patients with hormone receptor-positive cancers. Despite ET recommendations of 5 to 10 years of treatment, to the authors' knowledge there is little prospective study of its impact on cognitive function over an extended period of time. ET has known pharmacologic effects on the brain. Cognitive side effects are a concern for many women, with mixed findings reported in various studies. The current prospective longitudinal study examined the neuropsychological effects of ET over time, up to 6 years after treatment. METHODS: A total of 189 survivors of early-stage breast cancer enrolled in the study prior to initiating ET if prescribed, and were followed at 6 months (175 patients), 12 months (173 patients), and for 3 to 6 years (102 patients) with self-report and neuropsychological assessments. Using linear mixed models, the authors examined whether neuropsychological performance or impairment rates differed over time based on whether or not ET was received. RESULTS: The authors did not find any effect of ET on neuropsychological performance or impairment at any time point among survivors who received it compared with women who did not. However, those who participated in the 3-year to 6-year year visit demonstrated better executive function at baseline. CONCLUSIONS: In the current observational cohort study, no detrimental effect of ET on cognitive function was identified in survivors of early-stage breast cancer receiving treatment with ET compared with those who were not.
BACKGROUND: After treatment of primary breast cancer, endocrine therapy (ET) is prescribed for patients with hormone receptor-positive cancers. Despite ET recommendations of 5 to 10 years of treatment, to the authors' knowledge there is little prospective study of its impact on cognitive function over an extended period of time. ET has known pharmacologic effects on the brain. Cognitive side effects are a concern for many women, with mixed findings reported in various studies. The current prospective longitudinal study examined the neuropsychological effects of ET over time, up to 6 years after treatment. METHODS: A total of 189 survivors of early-stage breast cancer enrolled in the study prior to initiating ET if prescribed, and were followed at 6 months (175 patients), 12 months (173 patients), and for 3 to 6 years (102 patients) with self-report and neuropsychological assessments. Using linear mixed models, the authors examined whether neuropsychological performance or impairment rates differed over time based on whether or not ET was received. RESULTS: The authors did not find any effect of ET on neuropsychological performance or impairment at any time point among survivors who received it compared with women who did not. However, those who participated in the 3-year to 6-year year visit demonstrated better executive function at baseline. CONCLUSIONS: In the current observational cohort study, no detrimental effect of ET on cognitive function was identified in survivors of early-stage breast cancer receiving treatment with ET compared with those who were not.
Authors: Mackenzi Pergolotti; Nicolò Matteo Luca Battisti; Lynne Padgett; Alix G Sleight; Maya Abdallah; Robin Newman; Kathleen Van Dyk; Kelley R Covington; Grant R Williams; Frederiek van den Bos; YaoYao Pollock; Elizabeth A Salerno; Allison Magnuson; Isabella F Gattás-Vernaglia; Tim A Ahles Journal: J Geriatr Oncol Date: 2019-10-14 Impact factor: 3.599
Authors: M Lange; F Joly; J Vardy; T Ahles; M Dubois; L Tron; G Winocur; M B De Ruiter; H Castel Journal: Ann Oncol Date: 2019-12-01 Impact factor: 32.976
Authors: Andrew M Novick; Anthony T Scott; C Neill Epperson; Christopher D Schneck Journal: Front Neuroendocrinol Date: 2020-08-18 Impact factor: 8.606
Authors: Brenna C McDonald; Kathleen Van Dyk; Jeanne S Mandelblatt; Andrew J Saykin; Rachael L Deardorff; Jessica N Bailey; Wanting Zhai; Judith E Carroll; James C Root; Tim A Ahles Journal: Breast Cancer Res Treat Date: 2022-04-27 Impact factor: 4.624
Authors: Samantha J Mayo; Maryam Lustberg; Haryana M Dhillon; Zev M Nakamura; Deborah H Allen; Diane Von Ah; Michelle C Janelsins; Alexandre Chan; Karin Olson; Chia Jie Tan; Yi Long Toh; Jeong Oh; Lisa Grech; Yin Ting Cheung; Ishwaria Mohan Subbiah; Duska Petranovic; James D'Olimpio; Margherita Gobbo; Susanne Koeppen; Charles L Loprinzi; Linda Pang; Shivani Shinde; Olanipekun Ntukidem; Katherine B Peters Journal: Support Care Cancer Date: 2020-11-24 Impact factor: 3.603
Authors: Kathleen Van Dyk; Catherine M Crespi; Julienne E Bower; Judith E Carroll; Laura Petersen; Patricia A Ganz Journal: NPJ Breast Cancer Date: 2021-09-03
Authors: Andrew W Manigault; Patricia A Ganz; Michael R Irwin; Steve W Cole; Kate R Kuhlman; Julienne E Bower Journal: Transl Psychiatry Date: 2021-12-06 Impact factor: 6.222